Attitudes Towards Buprenorphine and Methadone

NCT ID: NCT00911846

Last Updated: 2009-06-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

180 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-05-31

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Main intention of this study is to find out whether there is a difference between the attitudes towards opioid- substitution of opioid dependent patients under substitution with methadone, buprenorphine or without substitution and their therapists

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Attitudes of patients and therapists can influence therapy success in both directions. Not much is known about patients' and their therapists' attitudes towards substitution medication. Our hypothesis is that the attitude towards buprenorphine is more positive than towards methadone even in patients taking methadone. Better knowledge about the influence of attitudes on treatment success could facilitate to adapt therapy to the patients' needs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Addictive Opioids

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Buprenorphine

opioid-dependent patients with buprenorphine substitution

interview

Intervention Type OTHER

interview using questionnaires

methadone

opioid-dependent patients substituted with methadone

interview

Intervention Type OTHER

interview using questionnaires

no substitution

opioid-dependent patients without substitution

interview

Intervention Type OTHER

interview using questionnaires

therapists

therapists of the patients

interview

Intervention Type OTHER

interview using questionnaires

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

interview

interview using questionnaires

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

questionnaire attitudes toward substitution

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 and 65 years
* Opioid-dependent with substitution with buprenorphine,
* methadone or without substitution
* Sufficient knowledge of German language

Exclusion Criteria

* Inability to give informed consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Psychiatric University Hospital, Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Psychiatric University Hospital Zurich

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lukas Boesch, PhD

Role: STUDY_CHAIR

Psychiatric University Hospital, Zurich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Psychiatric University Hospital

Zurich, Canton of Zurich, Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ria Leisinger, MD

Role: CONTACT

0041 44 384 27 87

Rudolf Stohler, MD

Role: CONTACT

0041 44 205 58 10

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ria Leisinger, MD

Role: primary

0041 44 384 27 87

Rudolf Stohler, MD

Role: backup

0041 44 205 58 10

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E-10/2009

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Buspirone in Opiate Withdrawal
NCT00326235 COMPLETED PHASE4
Distress Tolerance and Buprenorphine
NCT01556087 COMPLETED PHASE3
Buprenorphine Maintenance Protocol - 1
NCT00000205 COMPLETED PHASE3